je.st
news
Tag: therapies
Human Longevity Inc. (HLI) Launched To Promote Healthy Aging Using Advances In Genomics And Stem Cell Therapies
2014-03-05 05:58:20| drugdiscoveryonline News Articles
Human Longevity Inc. (HLI), a genomics and cell therapy-based diagnostic and therapeutic company focused on extending the healthy, high performance human life span, was announced today by co-founders J. Craig Venter, Ph.D.,Robert Hariri, M.D., Ph.D., and Peter H. Diamandis, M.D
Tags: human
cell
promote
healthy
Proteostasis Therapeutics Announces Extension Of Funded Collaboration With Cystic Fibrosis Foundation Therapeutics For Novel Therapies Targeting Most Common CF Mutation
2014-03-05 04:23:36| drugdiscoveryonline News Articles
Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with orphan and neurodegenerative diseases, recently announced an extension of its funded collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT)
Tags: common
foundation
extension
collaboration
Indiana Senate Passes Legislation to Ensure Safe Access to Biosimilar Therapies
2014-01-30 06:00:00| Industrial Newsroom - All News for Today
BIO and Indiana Health Industry Forum commend Indiana State Senate for passing legislation designed to create pathway for the substitution of interchangeable biologic medicines. Legislation ensures transparency and communication between patients and their treatment teams. Policies outlined in the identical SB 262 align with BIO’s principles on biologic substitution, therefore BIO and IHIF support passage of this bill as it moves along for consideration by the Indiana House of ...This story is related to the following:Trade Associations
Tags: access
safe
ensure
indiana
Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting
2013-11-02 14:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Sustained virologic response at post-treatment follow-up week 12 (SVR 12) seen in 100 percent of patients to date in two of the three combination arms studied WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the presentation of interim data from the ongoing C-WORTHY Study, a Phase II clinical trial evaluating the efficacy and safety of an all-oral regimen combining once-daily MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, with or without twice-daily ribavirin, administered for 12 weeks to treatment-nave, non-cirrhotic pat Language: English Contact: MerckMedia:Pamela Eisele, (908) 423-5042Sarra Herzog, (908) 423-6154orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Investing Smart: Biotechs, Effective Therapies And Shareholder-Friendly CEOs
2013-10-02 18:43:48| Biotech - Topix.net
There are many ways to invest in the clinical biotechnology space. You can invest in a clinical company during its early stages, while crossing your fingers that it becomes Acadia Pharmaceuticals and not Vical.
Tags: effective
smart
investing
therapies